ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

ACR Publishes National Research Agenda for 2016–2020

Kelly Tyrrell  |  July 6, 2016

Defining new therapeutic targets and developing new therapies are among the goals of the 2016–2020 ACR National Research Agenda. So, too, is understanding early disease states, defining triggers of autoimmunity and examining disparities in access to medication and treatment.1 Charting a Course Every five years, the Committee on Research (COR) is tasked with helping chart the…

Filed under:Legislation & AdvocacyPractice SupportProfessional Topics Tagged with:Committee on Researchtherapeutic targetsTherapies

Spanish Drugmaker Fears Disruption if EMA Moves from Britain

Emma Pinedo  |  July 4, 2016

MADRID (Reuters)—The likely relocation of the European Medicines Agency (EMA) from London threatens to disrupt the approval of new drugs and is a medium and long-term worry for top Spanish drugmaker Almirall, its chief executive says on Monday. The EMA, Europe’s equivalent the U.S. Food and Drug Administration, approves medicines for all European Union countries…

Filed under:Drug Updates Tagged with:European Medicines AgencyEuropean UnionInternationalpharmaceutical company

Arthritis Prevalence on the Rise, Creating Challenges for Healthcare System

Arthritis & Rheumatology  |  June 28, 2016

Updated projections suggest that arthritis and arthritis-attributable activity limitation will remain large and growing problems for clinical and public health systems, which must plan and create policies and resources to address these future needs. By 2040, the number of U.S. adults with doctor-diagnosed arthritis is projected to increase 49% to 78.4 million. Can the healthcare system accommodate these projected increases? Not without changes. By 2025, the expected demand for rheumatologists is expected to exceed supply by 2,576 adult and 33 pediatric rheumatologists…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:ArthritisArthritis & RheumatologyHealthcarephysical activityResearch

Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz

Michele B. Kaufman, PharmD, BCGP  |  June 22, 2016

The FDA is currently accepting comments on a draft guideline for osteoporosis treatments, which calls for more research into the long-term effects of drugs on bone quality. Also, the FDA has rejected an application for approval of Apadaz in its current form…

Filed under:AnalgesicsConditionsDrug UpdatesOsteoarthritis and Bone DisordersPain Syndromes Tagged with:Benzhydrocodone hydrochlorideChronic painFDAFood and Drug AdministrationGuidelinesOsteoporosispostmenopauseRegulation

Opinion: Erosive Changes Questioned in RA/Lupus Overlap Syndrome

George A.W. Bruyn, MD, PhD  |  June 13, 2016

I read with interest the Diagnostic View (TR, April), which, according to the authors, represented a case of rhupus, an overlap syndrome of RA and SLE. I challenge this view. My arguments: In the case of erosive RA, typically erosive changes are seen at MTP joints other than MTP1 (e.g., MTP5). In addition, the erosive…

Filed under:ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ArthritiserosionLupusMTP jointRheumatoid arthritisrhupusSLEsyndromeUric acid

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Diana M. Girnita, MD, PhD, Shahzad Safdar, MD, & Avis Ware, MD  |  June 13, 2016

Rheumatoid arthritis (RA) is rarely associated with renal manifestations, but secondary amyloidosis due to chronic inflammation is reported to be the etiology of renal dysfunction in many cases of RA.1,2 The discovery of biologic therapy, with TNF-alpha inhibitors in particular, made a huge difference in the disease course and prognosis of RA patients. However, TNF-alpha…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Autoimmunecase reportClinicalDiagnosisGlomerulonephritisimmune complexpatient careRenalRheumatoid arthritisrheumatologyTNF-Alpha inhibitor

Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 13, 2016

Etanercept Submitted for Chronic, Severe Plaque Psoriasis in Children The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application for etanercept (Enbrel) for treating pediatric patients with chronic, severe plaque psoriasis.1 The application was submitted in early January 2016 and is based on results of a one-year Phase 3 study with…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPediatric Conditions Tagged with:ApprovalsBiologicsBiosimilarsclinical trialsdrugetanerceptFDAknee painOsteoarthritisPediatricplaquePsoriasisrheumatologySafety

Treatments for Scleroderma with Gastrointestinal Involvement Address Symptoms

Thomas R. Collins  |  June 13, 2016

CHICAGO—Nine out of 10 scleroderma cases include clinical signs of gastrointestinal (GI) involvement, with severe involvement associated with high mortality rates, but the pathology of this is not very well understood, a GI expert said at the ACR’s State-of-the-Art Clinical Symposium. That has left clinicians with a slate of treatments—anti-reflux, antimicrobials and prokinetics—that address only…

Filed under:ConditionsResearch RheumSystemic Sclerosis Tagged with:2016 State-of-the-Art Clinical Symposiumgastrointestinalpatient careResearchSclerodermaTreatment

Email Remains Dominant Communications Method in Medicine

Richard Quinn  |  June 13, 2016

Forty-five years ago, a computer engineer in Boston sent an electronic message between two computers some 10 feet apart. It took another 10 years or so before the electronic mail message was dubbed email—a term now, perhaps, more ubiquitous than any other in the lexicon of modern communications. Despite the seemingly definitive place email communication…

Filed under:Practice SupportProfessional TopicsTechnology Tagged with:communicationemailFacebookGoogleHIPPAITpatient carephysicianprivacyrheumatologistSecuritySocial MediaTechnologyTwitter

Rheumatology Coding Corner Question: Office Visit with DEXA Scan

From the College  |  June 13, 2016

A 67-year-old female patient with Medicare returns to the office for a follow-up of her age-related osteoporosis. She states she has an achy pain in her left hip that lasts for 30–40 minutes in the morning. Currently, she has taken ibandronate sodium and alendronate sodium for the past year, and her pain level is a…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodingDEXA scanPractice Managementrheumatologistrheumatology

  • « Previous Page
  • 1
  • …
  • 161
  • 162
  • 163
  • 164
  • 165
  • …
  • 249
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences